TY - JOUR
T1 - Hepatotoxicity of contemporary antiretroviral drugs
T2 - A review and evaluation of published clinical data
AU - Otto, Ashley O.
AU - Rivera, Christina G.
AU - Zeuli, John D.
AU - Temesgen, Zelalem
N1 - Publisher Copyright:
© 2021 by the authors. Licensee MDPI, Basel, Switzerland.
PY - 2021/5
Y1 - 2021/5
N2 - Contemporary antiretroviral agents afford enhanced potency and safety for patients living with HIV. Newer antiretroviral drugs are often better tolerated than those initially approved in the early stages of the HIV epidemic. While the safety profile has improved, adverse drug reactions still occur. We have segregated the antiretroviral agents used in contemporary practice into class groupings based on their mechanism of antiviral activity (non-nucleoside reverse transcriptase inhibitors, nucleoside reverse transcriptase inhibitors, integrase inhibitors, protease inhibitors, and entry inhibitors) while providing a review and discussion of the hepatoxicity seen in the most relevant clinical literature published to date. Clinical literature for individual agents is discussed and agent comparisons afforded within each group in tabular format. Our review will provide a summative overview of the incidence and medications associated with hepatic adverse reactions linked to the use of contemporary antiretroviral drugs.
AB - Contemporary antiretroviral agents afford enhanced potency and safety for patients living with HIV. Newer antiretroviral drugs are often better tolerated than those initially approved in the early stages of the HIV epidemic. While the safety profile has improved, adverse drug reactions still occur. We have segregated the antiretroviral agents used in contemporary practice into class groupings based on their mechanism of antiviral activity (non-nucleoside reverse transcriptase inhibitors, nucleoside reverse transcriptase inhibitors, integrase inhibitors, protease inhibitors, and entry inhibitors) while providing a review and discussion of the hepatoxicity seen in the most relevant clinical literature published to date. Clinical literature for individual agents is discussed and agent comparisons afforded within each group in tabular format. Our review will provide a summative overview of the incidence and medications associated with hepatic adverse reactions linked to the use of contemporary antiretroviral drugs.
KW - Antiretroviral therapy
KW - Hepatotoxicity
KW - Human immunodeficiency virus
UR - http://www.scopus.com/inward/record.url?scp=85107398821&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85107398821&partnerID=8YFLogxK
U2 - 10.3390/cells10051263
DO - 10.3390/cells10051263
M3 - Review article
C2 - 34065305
AN - SCOPUS:85107398821
SN - 2073-4409
VL - 10
JO - Cells
JF - Cells
IS - 5
M1 - 1263
ER -